Pembrolizumab for patients with PD-L1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study - Mehnert, J M; Rugo, H S; O’Neil, B H (Ann Oncol, 2017)
. https://doi.org/10.1093/annonc/mdx368